|
Gastric Stomach Cancer Cure - Gastric Stomach Cancer Medicine Drug
TREATMENT CENTERS - SURVIVAL RATE - DRUGS AND MEDICINE - INFORMATION
- ATTORNEYS


Stomach cancer can develop in any part of the stomach and may spread
throughout the stomach and to other organs; particularly the
esophagus and the small intestine. Stomach cancer causes nearly one
million deaths worldwide per year.[1]
Contents [hide]
1 Epidemiology
2 Symptoms
3 Diagnosis
3.1 Histopathology
4 Staging
5 Treatment
5.1 Surgery
5.2 Chemotherapy
5.3 Radiation therapy
5.4 Multimodality therapy
5.5 Biological therapy
6 External links
7 References
[edit] Epidemiology
Stomach cancer represents roughly 2% (25,500 cases) of all new cancer
cases yearly in the United States, but it is much more common in
Korea, Japan, Great Britain, South America, and Iceland. It is
associated with high salt in the diet, smoking, and low intake of
fruits and vegetables. Infection with the bacterium H. pylori is the
main risk factor in about 80% or more of gastric cancers. It is more
common in men.
Gastric or stomach cancer has very high incidence in Korea and Japan.
Gastric cancer is the leading cancer type in Korea with 20.8% of
malignant neoplasms, the second leading cause of cancer deaths. It is
suspected several risk factors are involved including diet,
gastritis, intestinal metaplasia and Helicobacter pylori infection. A
Korean diet, high in salted, stewed and broiled foods, is thought to
be a contributing factor. Ten percent of cases show a genetic
component.[2] In Japan and other countries bracken consumption and
spores are correlated to stomach cancer incidence.[3] Epidemiologists
have yet to fully account for the high rates of gastric cancer as
compared to other countries. Gastric cancer shows a male predominance
in its incidence as up to 3 males are affected for every female.
Estrogen may protect women against the development of this cancer form.[4]
A very small percentage of diffuse-type gastric cancers (see
Histopathology below) are thought to be genetic. Hereditary Diffuse
Gastric Cancer (HDGC) has recently been identified and research is
ongoing. However, genetic testing and treatment options are already
available for families at risk.[5]
Metastasis occurs in 80-90% of individuals with stomach cancer, with
a five year survival rate of 75% in those diagnosed in early stages
and less than 30% of those diagnosed in late stages. The death rate
is 12,400 a year in the United States.
[edit] Symptoms
Endoscopic image of linitis plastica, a type of stomach cancer where
the entire stomach is invaded, leading to a leather bottle-like
appearance with blood coming out of it.Stomach cancer is often
asymptomatic or causes only nonspecific symptoms in its early stages.
By the time symptoms occur, the cancer has generally metastasized to
other parts of the body, one of the main reasons for its poor
prognosis. Stomach cancer can cause the following signs and symptoms:
Early
Indigestion or a burning sensation (heartburn)
Loss of appetite, especially for meat
Late
Abdominal pain or discomfort in the upper abdomen
Nausea and vomiting
Diarrhea or constipation
Bloating of the stomach after meals
Weight loss
Weakness and fatigue
Bleeding (vomiting blood or having blood in the stool), which can
lead to anemia
These can be symptoms of other problems such as a stomach virus,
gastric ulcer or tropical sprue and diagnosis should be done by a
gastroenterologist or an oncologist.
[edit] Diagnosis
To find the cause of symptoms, the doctor asks about the patient's
medical history, does a physical exam, and may order laboratory
studies. The patient may also have one or all of the following exams:
Gastroscopic exam is the diagnostic method of choice
Upper GI series (may be called barium roentgenogram)
Fecal occult blood test is obsolete except possibly as a screening
test; a negative test proves nothing and a positive result may result
from a large number of other conditions beside gastric carcinoma.
Abnormal tissue seen in a gastroscope examination will be biopsied by
the surgeon or gastroenterologist. This tissue is then sent to a
pathologist for histological examination under a microscope to check
for the presence of cancerous cells. A biopsy, with subsequent
histological analysis, is the only sure way to confirm the presence
of cancer cells.
A condition of darkened hyperplasia of the skin, frequently of the
axilla and groin, known as acanthosis nigricans, commonly prompts a
study into gastric carcinoma. It should be noted that this
hyperplasia can be found in obese individuals with no underlying cancer.
[edit] Histopathology
Poor to moderately differentiated adenocarcinoma of the stomach.
H&E stain.
Gastric signet ring cell carcinoma. H&E stain.Gastric
adenocarcinoma is a malignant epithelial tumor, originating from
glandular epithelium of the gastric mucosa. It invades the gastric
wall, infiltrating the muscularis mucosae, the submucosa and thence
the muscularis propria. Histologically, there are two major types of
gastric cancer (Lauren classification): intestinal type and diffuse type.
Intestinal type adenocarcinoma: tumor cells describe irregular
tubular structures, harboring pluristratification, multiple lumens,
reduced stroma ("back to back" aspect). Often, it
associates intestinal metaplasia in neighboring mucosa. Depending on
glandular architecture, cellular pleomorphism and mucosecretion,
adenocarcinoma may present 3 degrees of differentiation: well,
moderate and poorly differentiate.
Diffuse type adenocarcinoma (mucinous, colloid): Tumor cells are
discohesive and secrete mucus which is delivered in the interstitium
producing large pools of mucus/colloid (optically "empty"
spaces). It is poorly differentiated. If the mucus remains inside the
tumor cell, it pushes the nucleus at the periphery - "signet-ring
cell".
[edit] Staging
If cancer cells are found in the tissue sample, the next step is to
stage, or find out the extent of the disease. Various tests determine
whether the cancer has spread and, if so, what parts of the body are
affected. Because stomach cancer can spread to the liver, the
pancreas, and other organs near the stomach as well as to the lungs,
the doctor may order a CT scan, a PET scan, an endoscopic ultrasound
exam, or other tests to check these areas. Blood tests for tumor
markers, such as carcinoembryonic antigen (CEA) and carbohydrate
antigen (CA) may be ordered, as their levels correlate to extent of
metastasis, especially to the liver, and the cure rate.
Staging may not be complete until after surgery. The surgeon removes
nearby lymph nodes and possibly samples of tissue from other areas in
the abdomen for examination by a pathologist.
TNM staging is used
[edit] Treatment
Like any cancer, treatment is adapted to fit each person's individual
needs and depends on the size, location, and extent of the tumor, the
stage of the disease, and general health. Cancer of the stomach is
difficult to cure unless it is found in an early stage (before it has
begun to spread). Unfortunately, because early stomach cancer causes
few symptoms, the disease is usually advanced when the diagnosis is
made. Treatment for stomach cancer may include surgery, chemotherapy,
and/or radiation therapy. New treatment approaches such as biological
therapy and improved ways of using current methods are being studied
in clinical trials.
[edit] Surgery
Surgery is the most common treatment for stomach cancer. The surgeon
removes part (subtotal or partial gastrectomy) or all (total
gastrectomy) of the stomach, as well as some of the tissue around the
stomach, with the basic goal of removing all cancer and a margin of
normal tissue. Depending on the extent of invasion and the location
of the tumor, surgery may also include removal of part of the
esophagus, spleen, ovaries, intestine or pancreas . Tumors in the
lower parts of the stomach may call for a Billroth I or Billroth II
procedure. Endoscopic mucosal resection is a treatment for early
gastric cancer that has been pioneered in Japan, but is available in
the United States at some centers. In this procedure, the tumor is
removed from the wall of the stomach using an endoscope, with the
advantage in that it is a smaller operation than removing the
stomach. Surgical interventions are currently curative in less than
40% of cases, and, in cases of metastasis, may only be palliative.
[edit] Chemotherapy
Chemotherapy is the use of systemic drugs to fight the stomach
cancer. Unfortunately, gastric cancer has not been especially
sensitive to these drugs until recently, and historically served to
palliatively reduce the size of the tumor and increase survival time.
Some drugs used in stomach cancer treatment include: 5-FU
(fluorouracil), BCNU (carmustine), methyl-CCNU (Semustine), and
doxorubicin (Adriamycin), as well as Mitomycin C, and more recently
cisplatin and taxotere in various combinations. Scientists are
exploring the benefits of giving chemotherapy before surgery to
shrink the tumor, or as adjuvant therapy after surgery to destroy
remaining cancer cells. Combination treatment with chemotherapy and
radiation therapy is also under study. Doctors are testing a
treatment in which anticancer drugs are put directly into the abdomen
(intraperitoneal hyperthermic chemoperfusion). Chemotherapy also is
being studied as a treatment for cancer that has spread, and as a way
to relieve symptoms of the disease. The side effects of chemotherapy
depend mainly on the drugs the patient receives.
[edit] Radiation therapy
Radiation therapy (also called radiotherapy) is the use of
high-energy rays to damage cancer cells and stop them from growing.
When used, it is generally in combination with surgery and
chemotherapy, or used only with chemotherapy in cases where the
individual is unable to undergo surgery. Radiation therapy may be
used to relieve pain or blockage by shrinking the tumor for
palliation of incurable disease
[edit] Multimodality therapy
While previous studies of multimodality therapy (combinations of
surgery, chemotherapy and radiation therapy) gave mixed results, the
Intergroup 0116 (SWOG 9008) study[6] showed a survival benefit to the
combination of chemotherapy and radiation therapy in patients with
nonmetastatic, completely resected gastric cancer. Patients were
randomized after surgery to the standard group of observation alone,
or the study arm of combination chemotherapy and radiation therapy.
Those in the study arm receiving chemotherapy and radiation therapy
survived on average 36 months, compared to 27 months with
observation. .
[edit] Biological therapy
Biologic therapy is still in the testing stages for stomach cancer.
The side effects of biological therapy vary with the type of
treatment. Some cause flu-like symptoms, such as chills, fever,
weakness, nausea, vomiting, and diarrhea. Patients sometimes get a
rash, and they may bruise or bleed easily. These problems may be
severe, and patients may need to stay in the hospital during treatment.
[edit] External links
Article on Hereditary Diffuse Gastric Cancer
National Cancer Institute Gastric cancer treatment guidelines
Photos at: Atlas of Pathology
[edit] References
^ Cancer. World Health Organization (Feb 2006). Retrieved on 2007-05-24.
^ AHyuk-Joon Lee, Han-Kwang Yang, Yoon-Ok Ahn, Gastric cancer in
Korea Gastric Cancer, Volume 5, Number 3 / September, 2002. DOI:10.1007/s101200200031]
^ Alonso-Amelot ME, Avendano M., Human Carcinogenesis and Bracken
Fern: A Review of the Evidence, Curr Med Chem. 2002 Mar;9(6):675-86
^ Estrogen in the development of esophageal and gastric
adenocarcinoma (Thesis) http://diss.kib.ki.se/2007/978-91-7357-370-2/
^ Brooks-Wilson AR, Kaurah P, Suriano G, et al (2004). "Germline
E-cadherin mutations in hereditary diffuse gastric cancer: assessment
of 42 new families and review of genetic screening criteria". J.
Med. Genet. 41 (7): 50817. PMID 15235021.
^ Macdonald JS, Smalley SR, Benedetti J, et al (2001).
"Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction". N.
Engl. J. Med. 345 (10): 72530. PMID 11547741.
|